GLP-1 surge: Wegovy/Mounjaro + compounded/unapproved impurities/FDA warnings liver failure + Novo gaps 2 deaths + Lilly/peptides + Breezula + vegan/PM2.5 + Beers
Key Questions
What risks do compounded GLP-1 drugs pose?
Compounded GLP-1 like tirzepatide+B12 have impurities causing liver failure, often from China/Lilly sources. They fill shortages but lack safety. FDA warns against unapproved versions.
Why did FDA warn Novo Nordisk?
FDA cited Novo for safety reporting gaps on Ozempic/Wegovy, linked to two deaths. Failures in adverse event submissions violate regulations. Novo must correct promptly.
What are the weight loss surges for GLP-1 drugs?
Wegovy achieves 20.7% weight loss, Mounjaro/Zepbound/Retatrutide show strong results. Demand drives compounding despite risks. Clinical data supports efficacy.
What FDA actions on peptides like BPC-157?
FDA targets unapproved peptides and weight loss drugs with warning letters. Marketers face enforcement for safety violations. Peptides lack approval for claims.
How do lifestyle factors relate to GLP-1 trends?
Vegan diets link to lower cancer risk; PM2.5 pollution raises Alzheimer's odds. Breezula aids hair growth; exercise boosts VO2. Beers and habits influence health.
FDA warnings Apr7 unapproved GLP-1 Prime Sciences/Lovega/Gram infection risks; compounded tirzepatide impurities liver failure; Novo gaps/2 deaths; Wegovy 20.7%/Mounjaro/Retatrutide/Zepbound; peptides/BPC-157; Breezula/exer VO2/vegan cancer/PM2.5 Alz/Beers.